SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-001990
Filing Date
2023-01-27
Accepted
2023-01-27 16:35:55
Documents
13
Period of Report
2023-01-23
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K sabs20230123_8k.htm   iXBRL 8-K 29617
  Complete submission text file 0001437749-23-001990.txt   184104

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA sabs-20230123.xsd EX-101.SCH 4177
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE sabs-20230123_def.xml EX-101.DEF 14103
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sabs-20230123_lab.xml EX-101.LAB 18628
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sabs-20230123_pre.xml EX-101.PRE 14125
7 EXTRACTED XBRL INSTANCE DOCUMENT sabs20230123_8k_htm.xml XML 4820
Mailing Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104
Business Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104 605-679-6980
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

IRS No.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39871 | Film No.: 23563686
SIC: 2836 Biological Products, (No Diagnostic Substances)